Want to see SE:CAMX full AI Analyst Report?

Camurus AB (CAMX) Price & Analysis

8 Followers

CAMX Stock Chart & Stats

kr665.00

-kr17.00(-2.71%)

At close: Mar 06 4:00 PM EST

kr665.00

-kr17.00(-2.71%)

Day’s Range― - ―

52-Week Rangekr430.80 - kr754.50

Previous CloseN/A

Volume19.01K

Average Volume (3M)126.83K

Market Cap

kr33.05B

Enterprise Valuekr27.95B

Total Cash (Recent Filing)kr3.88B

Total Debt (Recent Filing)kr110.08M

Price to Earnings (P/E)48.3

Beta0.74

Next Earnings

Jul 15, 2026

EPS Estimate

3.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)11.49

Shares Outstanding59,989,185

10 Day Avg. Volume148,560

30 Day Avg. Volume126,834

Financial Highlights & Ratios

PEG Ratio0.73

Price to Book (P/B)8.62

Price to Sales (P/S)16.11

P/FCF Ratio49.93

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr700.00

Price Target Upside5.26% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)13.93

Revenue Forecast (FY)kr2.72B

Bulls Say, Bears Say

Bulls Say

High Margins & ProfitabilitySustained very high gross margins (~93%) and strong operating/net margins indicate durable unit economics from the FluidCrystal platform and proprietary products. These margins support reinvestment in R&D, drive solid ROE, and provide long-term cash flow cushion against cyclical pressures.

Conservative Balance SheetVery low leverage and growing equity/assets provide financial flexibility to fund development, commercialization and partnerships without strained liquidity. A strong balance sheet reduces refinancing risk and supports strategic investments or milestone-driven cash needs over the medium term.

Platform Validated By Lilly ExpansionEli Lilly’s expansion of the collaboration validates FluidCrystal and broadens its addressable market into cardiometabolic/amylin classes. The deal adds potential upfront, milestone and royalty streams, accelerating technology adoption and de‑risking commercial prospects through a major pharma partner.

Bears Say

Recent Revenue SoftnessA year‑over‑year revenue decline on a TTM basis signals weakening demand or commercialization headwinds that can pressure growth expectations. Even with strong margins, prolonged top‑line softness can slow milestone recognition, reduce leverage of fixed costs, and limit long‑term scalability.

Volatile Cash GenerationHistoric swings in operating and free cash flow indicate variability in cash conversion and timing of receipts (including milestone payments). This volatility complicates multi‑year planning, can force defensive funding choices in weak years, and raises execution risk for pipeline investments.

Partnership Revenue VariabilityReliance on milestone and royalty payments creates lumpiness and timing risk in revenue streams. Significant exposure to a few partner programs (even if large) concentrates commercial risk: partner development setbacks or reprioritization can materially delay or reduce expected cash inflows.

Camurus AB News

Camurus announces expansion of collaboration with Eli Lilly

Camurus (CAMRF) announced that Eli Lilly (LLY) has exercised its option to include amylin receptor agonists in the...

29d ago

LLY

Camurus Boosts Share Count to Support Employee Incentive Plan

Camurus AB ( ($SE:CAMX) ) has provided an update. Camurus AB has increased its total number of shares...

21h ago

Camurus hit by FDA manufacturing setback on U.S. acromegaly drug filing

Camurus AB ( ($SE:CAMX) ) has shared an announcement. Camurus said the U.S. Food and Drug Administration has...

20d ago

Camurus Targets Real‑World Evidence in New Acromegaly Study With Octreotide Depot

Camurus AB ($CAMRF) announced an update on their ongoing clinical study. Camurus AB has launched a new observational...

26d ago

CAMRF

Camurus Wins Lilly Option Exercise, Extending Long-Acting Cardiometabolic Drug Deal

Camurus AB ( ($SE:CAMX) ) has shared an announcement. Camurus has expanded its collaboration with Eli Lilly after...

29d ago

Camurus Repurchases Series C Shares to Fund Long-Term Incentive Plan

The latest announcement is out from Camurus AB ( ($SE:CAMX) ). Camurus’ board has moved to secure share...

1M ago

Camurus AGM Backs Board, Withholds Dividend and Approves New Performance Share Plan

Camurus AB ( ($SE:CAMX) ) has provided an update. At its 2026 annual general meeting in Lund, Camurus...

1M ago

Camurus Holds Course on 2026 Outlook Despite Softer Q1 Sales

Camurus AB ( ($SE:CAMX) ) has issued an announcement. Camurus reported first-quarter 2026 revenues of SEK 533 million,...

2M ago

Camurus Targets Severe Diseases With Long-Acting Drug Innovations

The latest update is out from Camurus AB ( ($SE:CAMX) ). Camurus highlights its mission to address significant...

2M ago

Camurus calls 2026 AGM with capital measures and new incentive plan on agenda

An announcement from Camurus AB ( ($SE:CAMX) ) is now available. Camurus AB has convened its 2026 annual...

2M ago

Camurus Expands Share Capital After Employee Stock Option Exercises

The latest update is out from Camurus AB ( ($SE:CAMX) ). Camurus AB has increased its share capital...

3M ago

Camurus announces FDA acceptance of NDA resubmission for Oclaiz

Camurus (CAMRF) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of...

6M ago

Camurus upgraded to Buy from Hold at DNB Carnegie

DNB Carnegie analyst Erik Hultgard upgraded Camurus (CAMRF) to Buy from Hold with an SEK 800 price target...

12M ago

Camurus, Lilly enter collaboration pact for long-acting FluidCrystal incretins

Camurus (CAMRF) and Eli Lilly (LLY) have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights...

1y ago

LLY

CAMX FAQ

What was Camurus AB’s price range in the past 12 months?

Camurus AB lowest stock price was kr430.80 and its highest was kr754.50 in the past 12 months.

What is Camurus AB’s market cap?

Camurus AB’s market cap is kr33.05B.

When is Camurus AB’s upcoming earnings report date?

Camurus AB’s upcoming earnings report date is Jul 15, 2026 which is in 14 days.

How were Camurus AB’s earnings last quarter?

Camurus AB released its earnings results on May 12, 2026. The company reported kr2.45 earnings per share for the quarter, missing the consensus estimate of kr3.471 by -kr1.021.

Is Camurus AB overvalued?

According to Wall Street analysts Camurus AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Camurus AB pay dividends?

Camurus AB does not currently pay dividends.

What is Camurus AB’s EPS estimate?

Camurus AB’s EPS estimate is 3.45.

How many shares outstanding does Camurus AB have?

Camurus AB has 59,989,185 shares outstanding.

What happened to Camurus AB’s price movement after its last earnings report?

Camurus AB reported an EPS of kr2.45 in its last earnings report, missing expectations of kr3.471. Following the earnings report the stock price went down -8.807%.

Which hedge fund is a major shareholder of Camurus AB?

Currently, no hedge funds are holding shares in SE:CAMX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Camurus AB (CAMX) Earnings & Revenues

Historic Earnings Reports

CAMX Company Deck

CAMX Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented a broadly positive strategic and financial picture for Camurus: full-year revenue and operating profitability improved materially, net cash increased significantly, regulatory approvals and U.S. FDA acceptance (PDUFA set) support upcoming launches, Brixadi royalties showed strong growth, and early-stage R&D (CAM2056) delivered compelling data. At the same time, the company faces notable short-term headwinds: Q4 revenue and product sales were down due to a U.K. distribution change and FX effects, quarter operating profit contracted, access/reimbursement barriers in several large European markets constrain Buvidal upside, and timing uncertainty remains for the SORENTO readout and some milestone revenues. Management provided constructive 2026 guidance while flagging planned increases in OpEx tied to U.S. launch preparation. Overall, strengths in commercial traction, cash position, approvals, and pipeline momentum outweigh the near-term operational and market-access challenges.View all SE:CAMX earnings summaries

CAMX Stock 12 Month Forecast

Average Price Target

kr700.00

▲(5.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"482":"kr482","719":"kr719","541.25":"kr541.3","600.5":"kr600.5","659.75":"kr659.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr700.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr700.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr700.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[482,541.25,600.5,659.75,719],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,553,564.3076923076923,575.6153846153846,586.9230769230769,598.2307692307693,609.5384615384615,620.8461538461538,632.1538461538462,643.4615384615385,654.7692307692307,666.0769230769231,677.3846153846154,688.6923076923077,{"y":700,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,553,564.3076923076923,575.6153846153846,586.9230769230769,598.2307692307693,609.5384615384615,620.8461538461538,632.1538461538462,643.4615384615385,654.7692307692307,666.0769230769231,677.3846153846154,688.6923076923077,{"y":700,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,553,564.3076923076923,575.6153846153846,586.9230769230769,598.2307692307693,609.5384615384615,620.8461538461538,632.1538461538462,643.4615384615385,654.7692307692307,666.0769230769231,677.3846153846154,688.6923076923077,{"y":700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":515.5,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":607,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":669,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":718,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":690.5,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":624.5,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":604,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":616,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":687,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":483.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":531,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":553,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >